Somnomed Ltd has released a press release.
Strong Q4 growth to finish transitional year
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Somnomed
- Renew Sleep Solutions well ahead of plan
- Renew Sleep Solutions opens first two centres in Q2
- Sales growth accelerating
- FDA 510k approval for SomnoDent Alpha
- Strong finish to the financial year for SomnoMed
Later from Somnomed
- Good revenue growth for the quarter
- Revenue growth up 45% in Q2
- ASX Market Release - Trading Halt
- Accelerated non-renounceable entitlement offer
- Successful completion of Institutional Entitlement Offer
Follow Somnomed into a list and get an email when it puts out news.
Follow Somnomed